Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nurix Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Nurix Therapeutics, Inc.

NRIX

Nurix Therapeutics, Inc.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a biopharmaceutical company specializing in targeted protein degradation therapies for cancer and inflammatory diseases. Utilizing AI-driven discovery platforms, it develops novel degraders and degrader antibody conjugates targeting previously undruggable proteins. Its pipeline includes clinical and preclinical drug candidates, with collaborations generating significant non-dilutive funding. The company's core focus is on innovative, mechanism-based treatments that expand therapeutic options and address drug resistance.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Nurix Therapeutics, Inc.

1
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports 66% Revenue Decline and Increased Net Loss in Latest Quarter

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports $264.5M Net Loss and $84M Revenue for Fiscal Year Ended November 30, 2025

Via official filing (AI summary) | 5 months ago | 0 comments

3
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports Q3 2025 Revenue Decline to $7.9 Million, Increased Net Loss

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports $44.1 Million Revenue for Quarter Ending May 31, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports 11.3% Revenue Growth, $56.4 Million Net Loss for Quarter Ended February 28, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nurix Therapeutics, Inc. Nurix Therapeutics Reports Increased Assets, Decline in Revenue, and Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments